Mark Sommerfeld,Hans-Ludwig Schaefer,Oliver Boscheinen,Paul Habermann,Ercole Rao,Matthias Dreyer
申请号：
US15059001
公开号：
US20160279199A1
申请日:
2016.03.02
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
